Trimel TLRTSX

Investor Fact Sheet
Name

Trimel Pharmaceuticals Corporation

Business Description 

Trimel is a specialty pharmaceutical company developing medications for male hypogonadism, female sexual dysfunction, and various respiratory disorders.  The Corporation holds a licence for the development and marketing rights to certain products utilizing a bioadhesive intranasal gel drug delivery technology platform and owns a novel unit-dose dry power inhaler / nasal dispersion system (“TriVair™”).  The Corporation is pursuing the development and application of these technologies for therapeutic categories such as (a) male hypogonadism, (b) female orgasmic disorder, and (c) respiratory disorders, which are significant market opportunities in the United States.

The Corporation’s drug delivery technology platforms are intended to create products that are expected to be safer, more effective, easy to use and more practical than in circumstances where competitive products are on the market.  Since the Corporation’s inception, it has focused on the optimization of known high volume pharmaceutical compounds in order to improve their performance and utilization by physicians and patients.

Stock Exchange

Toronto Stock Exchange (TSX)
 

Stock Symbol

TRL

Shares Outstanding 

163.13 Million

 Head Office

2488 Dunwin Drive
Mississauga, Ontario, Canada
L5L 1J9
T: (416) 679-0771
F: (905) 569-1809

 Chairman

Mr. Ian Ihnatowycz

President & Chief Executive Officer

Mr. Tom Rossi

Chief Financial Officer

Mr. Kenneth G. Howling

 Auditor

PricewaterhouseCoopers LLP

Transfer Agent

Equity Financial Trust Company

 Analyst Coverage
Name 
 
Institution
 
E-mail Address
 
Phone Number
 
Alan Ridgeway
 
Paradigm Capital
 
aridgeway@paradigmcap.com   
 
(416) 361-9080  
 
Douglas Miehm  
 
RBC Capital Markets
 
douglas.miehm@rbccm.com
 
(416) 842-7823
 
Scott Henry
 
 Roth Capital Partners  
 
shenry@roth.com
 
(949) 720-7123
 
Regulatory Filings To access Trimel's SEDAR filings, please click on the following link:
 

Trimel Pharmaceuticals Corporation SEDAR Profile Page

 

© 2014 by Trimel Pharmaceuticals Corporation